160 related articles for article (PubMed ID: 20059374)
1. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
Kontoghiorghes GJ; Kolnagou A; Peng CT; Shah SV; Aessopos A
Expert Opin Drug Saf; 2010 Mar; 9(2):201-6. PubMed ID: 20059374
[TBL] [Abstract][Full Text] [Related]
2. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
3. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
Porter JB; Davis BA
Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
[TBL] [Abstract][Full Text] [Related]
4. Optimizing iron chelation strategies in beta-thalassaemia major.
Porter JB
Blood Rev; 2009 Dec; 23 Suppl 1():S3-7. PubMed ID: 20116637
[TBL] [Abstract][Full Text] [Related]
5. Current approach to iron chelation in children.
Aydinok Y; Kattamis A; Viprakasit V
Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
[TBL] [Abstract][Full Text] [Related]
6. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
Taher A; Hershko C; Cappellini MD
Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
8. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation: an update.
Sheth S
Curr Opin Hematol; 2014 May; 21(3):179-85. PubMed ID: 24504090
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
11. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
12. Deferiprone: new preparation. Poorly assessed.
Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
[TBL] [Abstract][Full Text] [Related]
13. A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Kontoghiorghes GJ
Expert Opin Drug Saf; 2013 Sep; 12(5):605-9. PubMed ID: 23688354
[TBL] [Abstract][Full Text] [Related]
14. The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):199-203. PubMed ID: 20524809
[TBL] [Abstract][Full Text] [Related]
15. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Kalinowski DS; Richardson DR
Chem Res Toxicol; 2007 May; 20(5):715-20. PubMed ID: 17402750
[TBL] [Abstract][Full Text] [Related]
16. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
Kontoghiorghes GJ
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069073
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.
Kontoghiorghe CN; Kolnagou A; Kontoghiorghes GJ
Expert Opin Investig Drugs; 2013 May; 22(5):591-618. PubMed ID: 23586878
[TBL] [Abstract][Full Text] [Related]
18. The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):1-4. PubMed ID: 22900514
[TBL] [Abstract][Full Text] [Related]
19. Iron Chelation for Iron Overload in Thalassemia.
Crisponi G; Nurchi VM; Lachowicz JI
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855104
[TBL] [Abstract][Full Text] [Related]
20. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.
Di Maggio R; Maggio A
Br J Haematol; 2017 Sep; 178(5):676-688. PubMed ID: 28439891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
